Amber Weissenfluh
Director, Pharmaceutical Development at Viking Therapeutics, Inc. - San Diego, CA, US
Amber Weissenfluh's Colleagues at Viking Therapeutics, Inc.
Amber Weissenfluh's Contact Details
858-704-4660
Viking Therapeutics, Inc.
Amber Weissenfluh's Company Details
Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our most advanced candidate is a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 trial for the treatment recovery from hip fracture surgery. Our thyroid receptor beta (TRb) agonist platform, also in Phase 2, is being developed for lipid disorders such as hypercholesterolemia and fatty liver diseases such as non-alcoholic steatohepatitis (NASH) as well as for rare diseases of glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy, or X-ALD. See more at http://www.vikingtherapeutics.com